PHILADELPHIA, Dec. 17, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that it has scheduled an Investor Conference Call and webcast to take place on Wednesday, December 19, 2007 at 4:00 p.m. EST. Dr. William Carter, Chairman and CEO, will discuss the recently announced licensing/research agreements with vaccine manufacturers for the use of the Company's experimental drug Ampligen(r) as an immune enhancer to influenza vaccines. The discussion will also include market data from PricewaterhouseCoopers which includes information on vaccine developments, Toll Like Receptors (TRL) under development, as well as the cost parameters of such development. As part of a continuation from last week's conference call, discussion will also focus on the pre-clinical comments cited by the U.S. Food and Drug Administration regarding the company's New Drug Application for the potential treatment of Chronic Fatigue Syndrome.
Interested parties are encouraged to access the PricewaterhouseCoopers market data prior to the conference call. This information will be available on the company's website at http://www.hemispherx.net on Tuesday, December 18th.
To access the conference call:
U.S. Callers: 800-346-7359 International Callers: 973-528-0008 Conference Entry Code: 719555
This call will be webcast via the Company's website at: http://www.hemispherx.net.
The call will also be available for replay until January 1st, 2008 at:
U.S. Callers: 800-332-6854 International Callers: 973-528-0005 Conference Entry Code: 719555
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) and the experimental therapeutics Ampligen(r), Alferon LDO and Oragens(r). Alferon N Injection(r) is approved for a category of STD infection, and Ampligen(r) and Oragens(r) represent a large portfolio of experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 90 issued patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection(r)) and a GMP certified manufacturing facility for its novel pharma products. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technology addresses. For more information please visit www.hemispherx.net.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications.